Detalhe da pesquisa
1.
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
Invest New Drugs
; 38(6): 1784-1795, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436060
2.
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Clin Cancer Res
; 27(16): 4511-4520, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083232
3.
Bispecific Antibodies in the Treatment of Hematologic Malignancies.
Clin Pharmacol Ther
; 106(4): 781-791, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770546
4.
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
J Clin Oncol
; 32(36): 4134-40, 2014 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25385737